COMPASS Pathways plc is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people who are suffering with mental health challenges. Our first major initiative is developing psilocybin therapy for treatment-resistant depression (TRD). We are currently running the world’s first large-scale psilocybin therapy clinical trial, in 20 sites across Europe and North America. We received FDA Breakthrough Therapy designation for our programme of psilocybin therapy for TRD in 2018. Since September 2020, we have been a public company listed on Nasdaq under the ticker CMPS.